<DOC>
	<DOCNO>NCT00995345</DOCNO>
	<brief_summary>The purpose study assess safety effectiveness KRP-104 glycemic control patient type 2 diabetes inadequately control metformin alone .</brief_summary>
	<brief_title>Safety Efficacy Once-Daily KRP-104 Type 2 Diabetics With Inadequate Glycemic Control Metformin Alone</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Patients meet follow criterion screen visit ( Visit 1 ) eligible participate trial : 1 . Signed write informed consent ; 2 . Males females 18 75 year age , inclusive ; 3 . Females childbearing potential must agree use 2 adequate form barrier method contraception ( eg , latex condom AND intrauterine device diaphragm ) avoid pregnancy study ; 4 . On stable dose ( Greater equal 10 week dose ) metformin monotherapy ( Less equal 1500 mg/day maximum tolerate dose ) , HbA1c great equal 7.0 % less equal 10.5 % ; On metformin ( less equal 1500 mg/day ) 1 antidiabetic agent ( exclude TZD , insulin , incretin therapy [ DPP4 inhibitor GLP1 analogue ] ) HbA1c great equal 6.8 % less equal 10.0 % ; Not antidiabetic therapy ( least 3 month prior Visit 1 ) stable dose metformin monotherapy 10 week HbA1c great equal 8.0 % less equal 11.0 % . 1 . History type 1 diabetes mellitus history diabetic ketoacidosis persistent hypoglycemia ; 2 . History presence alcoholism drug abuse within 2 year prior dose ; 3 . Typical consumption great equal 10 drink alcohol weekly ; 4 . Presence follow condition : Significant renal impairment ( glomerular filtration rate le 60 mL/min ) ; Diabetic gastroparesis ; Active liver disease ( asymptomatic nonalcoholic fatty liver disease ) , cirrhosis , symptomatic gallbladder disease ; 5 . Fasting plasma glucose/blood glucose great 240 mg/dL ( 13.3 mmol/L ) Visit 3 ( Week 2 ) ( 1 laboratory retest permit ) ; 6 . Body mass index less equal 20 kg/m2 great equal 48 kg/m2 ; 7 . Systolic blood pressure &lt; 100 mmHg &gt; 160 mmHg diastolic blood pressure &lt; 50 mmHg &gt; 100 mmHg Visit 3 ( Note : medication control blood pressure allow optimized stabilized prior Visit 3 ) ; 8 . Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 2 X upper limit normal ( ULN ) ( 1 laboratory retest permit ) ; 9 . Creatine phosphokinase ( CPK ) great 2 X ULN ( explain muscular trauma exercise ) ( 1 laboratory retest permit ) ; 10 . Serum creatinine &gt; 1.5 mg/dL male ( 132.6 μmol/L ) 1.4 mg/dL female ( 123.8 μmol/L ) ; 11 . Fasting triglyceride ( TG ) &gt; 600 mg/dL ( 6.78 mmol/L ) Visit 3 ( Week 2 ) ( Note : diet/exercise lipidlowering medication control elevate TG allow ; medication optimize stabilize prior Visit 3 ) ; 12 . Treatment pioglitazone rosiglitazone within previous 10 week ( Visit 1 ) ; treatment incretin therapy ( DPP4 inhibitor GLP1 analogue ) within previous 4 week ( Visit 1 ) ; 13 . Treatment type insulin ( ie , injected inhale ) within previous 3 month ; 14 . Must meet laboratory Medical History clinical criterion . Please contact recruitment center referral</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Type 2 Diabetes</keyword>
	<keyword>Metformin</keyword>
</DOC>